PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home » Neonatal Abstinence Syndrome

Psychiatric Times. Vol. 23 No. 6
Pages: 1  2  
Previous
 

Psychopharmacologic Therapy in Pregnancy: Effects on Newborns

By Emilio J. Sanz, MD, PhD and Carlos De las Cuevas, MD, PhD | May 1, 2006

Antiepileptic drugs (AEDs)

A mother's use of AEDs is linked to the immediate withdrawal effects of the newborn and to long-term neurologic dysfunctions. Valproate(Drug information on valproate) was shown to be associated with immediate NWS symptoms, such as hyperexcitability, causing neurologic deficits, seizures, and jitteriness.32,33 Furthermore, in a retrospective study based on hospital records, Dean and associates34 found significant NWS symptoms, including jitteriness, hypotonia, seizures, apneic episodes, hypoglycemia, and feeding disorder, after exposure in utero to valproate, phenytoin(Drug information on phenytoin), or combination therapy.

Long-term effects of AEDs have also been demonstrated. In the study by Koch and associates,32 when children were examined 6 years later, they continued to have long-term neurologic dysfunctions, which are more congruent with drug toxicity than withdrawal effects. Similar results are reported in the study by Moore and associates33 of 57 children prenatally exposed to AEDs: 77% had learning difficulties, 81% had speech delay, 60% had gross motor delay, and 42% had fine motor delay. Eighty percent of these children had prenatal exposure to valproate alone or in combination with another AED. Seventy-four percent of school-aged children were enrolled in special education classes or were receiving learning support, and 81% had some type of behavioral dysfunction; of these, 60% had some autistic features and 39% had hyperactivity, but autism or Asperger syndrome had actually been diagnosed in only a few. The developmental effects seem to be associated not only with valproate but also with carbamazepine(Drug information on carbamazepine), phenytoin, and polypharmacy.34 Although these investigators did not find a link between NWS and cognitive dysfunction, this is a topic in which further research is badly needed.

Conclusions

Pregnant women with psychiatric conditions must be adequately treated. Pharmacologic treatment should be initiated or maintained when the disorder is severe and the efficacy of the psychopharmacologic approach has been demonstrated, giving attention to nonpharmacologic alternatives in order to prevent the relapse of the disease in the mother. Psychiatric clinical practice shows that most pregnant women with psychiatric conditions are treated with polypharmacy,35 making it even more complex to identify the effects of these drugs on the newborn. Psychopharmacologic agents can induce direct effects on the newborn, as well as withdrawal symptoms associated with their suppression. The clinical picture of both cases is often similar and confounding. Nevertheless, NWS has clearly been associated with TCAs, SSRIs, and AEDs. However, with the exception of AEDs, the clinical picture for most of these drugs appears to be self-limited and moderate, most frequently needing only supportive therapy.

Dr Sanz is associate professor in clinical pharmacology at the University of La Laguna in Tenerife, Canary Islands, Spain, and a member of the Review Panel of Experts of the WHO Collaborating Centre for International Drug Monitoring. He reports that he has no conflicts of interest concerning the subject matter of this article.

Dr De las Cuevas is associate professor of psychiatry at the University of La Laguna in Tenerife, Canary Islands, Spain, a specialist in psychiatry with clinical responsibilities, and a senior member of the Educational Liaisons Network of the World Psychiatric Association. He reports that he has no conflicts of interest concerning the subject matter of this article.

Pages: 1  2  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





Drugs Mentioned in This Article

Alprazolam (Xanax)
Carbamazepine (Carbatrol, Tegretol, others)
Citalopram (Celexa)
Diazepam (Valium)
Fluoxetine (Prozac)
Paroxetine (Paxil)
Pentylenetetriazol (Metrazol)
Phenytoin (Dilantin)
Valproate/Valproic acid (Depakote, others)

References

1. Altshuler LL, Hendrick V, Cohen LS. An update on mood and anxiety disorders during pregnancy and the postpartum period. Prim Care Companion J Clin Psychiatry. 2000;2:217-222.
2. Andersson L, Sundstrom-Poromaa I, Bixo M, et al. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population based study. Am J Obstet Gynecol. 2003;189:148-154.
3. Bennett HA, Einarson A, Taddio A, et al. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004;103:698-709.
4. Goldstein DJ, Sundell K. A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Hum Psychopharmacol Clin Exp. 1999;14: 319-324.
5. Kohen D. Psychotropic medication in pregnancy. Adv Psychiatric Treat. 2004;10:59-66.
6. Ward RK, Zamorski MA. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician. 2002;66:629-636.
7. NSW Health. Neonatal Abstinence Syndrome Guidelines. Available at: http://www.health.nsw.gov.au/policies/ pd/2005/PD2005_494.html. Accessed March 23, 2006.
8. American Academy of Pediatrics: Committee on Drugs. Neonatal drug withdrawal. Pediatrics. 1998; 101:1079-1088.
9. Desmond MM, Rudolph AJ, Hill RM, et al. Behavioral alterations in infants born to mothers on psychoactive medication during pregnancy. In: Farrell G, ed. Congenital Mental Retardation. Austin, Tex: University of Texas Press; 1967:235-245.
10. Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol. 1992;14:399-406.
11. Lee A, Inch S, Finnigan D. Therapeutics in Pregnancy and Lactation. Oxfordshire, UK: Radcliffe Medical Press Ltd; 2000.
12. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24:183-197.
13. Musa AB, Smith CS. Neonatal effects of maternal clomipramine therapy. Arch Dis Child. 1979;54:405.
14. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. Br Med J (Clin Res Ed). 1982;284: 1837-1838.
15. Singh S, Gulati S, Narang A, Bhakoo ON. Nonnarcotic withdrawal syndrome in a neonate due to maternal clomipramine therapy. J Paediatr Child Health. 1990;26:110.
16. Schimmell MS, Katz EZ, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol. 1991;29:479-484.
17. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
18. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
19. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288-291.
20. Sanz EJ, De las Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
21. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061.
22. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediat Adolesc Med. 2002;156:1129-1132.
23. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60: 720-726.
24. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics. 1992;23:18-23.
25. Gilstrap LC, Little BB. Drugs and Pregnancy. Toronto: Chapman and Hall; 1998.
26. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatric Serv. 2002;53:39-49.
27. Bertilsson L, Henthorn T, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45:348-355.
28. Jaiswal AK, Bhattacharya SK. Effects of gestational undernutrition, stress and diazepam treatment on spatial discrimination learning and retention in young rats. Indian J Exp Biol. 1993;31:353-359.
29. Christensen HD, Gonzalez CL, Rayburn WF. Effects from prenatal exposure to alprazolam on the social behaviour of mice offspring. Am J Obstet Gynecol. 2003;189:1452-1457.
30. Jaiswal AK. Effects of prenatal alprazolam exposure on anxiety patterns in rat offspring. Indian J Exp Biol. 2002;40:35-39.
31. Nicosia A, Giardina L, Di Leo F, et al. Long-lasting behavioral changes induced by pre- or neonatal exposure to diazepam in rats. Eur J Pharmacol. 2003;469:103-109.
32. Koch S, Jager-Roman E, Losche G, et al. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. Acta Paediatr. 1996;85:739-746.
33. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet. 2000;37:489-497.
34. Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002;39:251-259.
35. De las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands.BMC Psychiatry. 2004;4:18.


 
RELATED TOPICS
Munchasuen syndrome
Substance Abuse
Opioid-related disorders
Neonatal abstinence syndrome
Cocaine-related disorders
Morphine dependence
Substance-related disorders
Substance abuse detection
Intravenous substance abuse
Eating disorders
Gambling
Trichotillomania
Physiological Sexual Dysfunction
Sexual Child Abuse
Sexual Harassment
Psychological Sexual Dysfunctions
Sexual And Gender Disorders
Social Behavior
Sex differentiation disorders
Sadism
Masochism
Internet Addiction

 


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Developmental Psychopathology Comes of Age
  • The Moral Struggles of Practicing Psychiatrists
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Developmental Psychopathology Comes of Age
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Psychiatry and the Myth of “Medicalization”
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
  • Will Your Clinical Records Support You in Court?
  • Refinements in ECT Techniques
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Psychiatry and the Myth of “Medicalization”
  • Grief and Depression: The Sages Knew the Difference
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • Diagnosis and its Discontents: The DSM Debate Continues
  • Lamotrigine for Major Depressive Disorder Is Inappropriate
  • New Insight Into the Neurobiology of Depression
  • Tie One On for Patients
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • Psychiatry and the Myth of “Medicalization”
  • Parity Laws: Powerful Weapon—or Pipe Dream?
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
CME
Breaking the Cycle of Substance Abuse and Addiction: Focus on Management Strategies
Approaching Crossroads in Psychiatry: Eating Disorders, Suicide and Substance Abuse
More Addiction CME


 
SEARCH MEDICA

Find peer-reviewed literature and websites for practicing medical professionals

CME on Neonatal Abstinence Syndrome
Evidence on Neonatal Abstinence Syndrome
Guidelines on Neonatal Abstinence Syndrome
Patient Education on Neonatal Abstinence Syndrome
Clinical Trials on Neonatal Abstinence Syndrome
Practical Articles on Neonatal Abstinence Syndrome
Research and Reviews on Neonatal Abstinence Syndrome
All "Neonatal Abstinence Syndrome" results


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy